![moa of glp-1 agonists Mechanism action of [25] Mechanism of action of GLP-1](https://www.researchgate.net/publication/256289222/figure/fig1/AS:614177232142337@1523442671231/Mechanism-of-action-of-GLP-1-25.png)
moa of glp-1 agonists Mechanism action of [25] Mechanism of action of GLP-1
Description
Start your weight-loss journey for the last time.
Strategies to facilitate medication adherence, persistence and treatment intensification in people with T2D should be made a priority in order to achieve and maintain glycaemic targets and improve outcomes in this population
![moa of glp-1 agonists Mechanism action of [25] Mechanism of action of GLP-1](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-024-02300-6/MediaObjects/592_2024_2300_Fig1_HTML.png)
Explore BPS Biosciences solutions for GLP-1R research in diabetes
![moa of glp-1 agonists Mechanism action of [25] Mechanism of action of GLP-1](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-024-01931-z/MediaObjects/41392_2024_1931_Fig6_HTML.png)
By Sabina Paglialunga, PhD & Aernout van Haarst, PhD Senior Directors Scientific Affairs Glucagon-Like Peptide-1 (GLP-1) receptor agonists first came to the market in 2005 as a type 2 diabetes mellitus treatment, and they have been making headlines again for their weight reduction effects
![moa of glp-1 agonists Mechanism action of [25] Mechanism of action of GLP-1](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12933-021-01412-5/MediaObjects/12933_2021_1412_Fig1_HTML.png)
